1. Home
  2. KEY vs NTRA Comparison

KEY vs NTRA Comparison

Compare KEY & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KeyCorp

KEY

KeyCorp

HOLD

Current Price

$19.37

Market Cap

20.8B

Sector

Finance

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$244.06

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEY
NTRA
Founded
1825
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.8B
27.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
KEY
NTRA
Price
$19.37
$244.06
Analyst Decision
Buy
Strong Buy
Analyst Count
14
16
Target Price
$20.11
$227.69
AVG Volume (30 Days)
17.6M
1.7M
Earning Date
01-20-2026
11-06-2025
Dividend Yield
4.26%
N/A
EPS Growth
34785.88
N/A
EPS
0.86
N/A
Revenue
$5,934,000,000.00
$2,116,676,000.00
Revenue This Year
$77.19
$32.77
Revenue Next Year
$6.55
$16.51
P/E Ratio
$22.27
N/A
Revenue Growth
22.30
38.17
52 Week Low
$12.73
$125.38
52 Week High
$19.73
$245.59

Technical Indicators

Market Signals
Indicator
KEY
NTRA
Relative Strength Index (RSI) 68.96 80.03
Support Level $18.26 $233.67
Resistance Level $18.68 $240.18
Average True Range (ATR) 0.42 7.39
MACD 0.17 0.68
Stochastic Oscillator 83.51 97.49

Price Performance

Historical Comparison
KEY
NTRA

About KEY KeyCorp

With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: